Summary
PROJECT SUMMARY Non-metastatic breast cancer is treated surgically and with adjuvant therapies. As these treatments have improved, recurrence-free survival has steadily increased, and late recurrence (recurrence beyond 10 years’ survival) has become a pressing issue for patients and providers. There are existing and emerging therapies that prophylactically target dormant breast tumors to prevent late recurrence. However, these therapies carry substantial toxicities and should only be used in women who are at high risk for late recurrence. No prognostic assay is recognized by the American Socie
